Close Menu

NEW YORK- A consortium led by Vancouver, Canada-based Canexia Health (formerly Contextual Genomics) has launched a C$2,590,500 (US$1.9 million) initiative that aims to improve access to testing and treatment options for Canadian cancer patients during the coronavirus pandemic.

The initiative, named Project ACTT (Access to Cancer Testing and Treatment), will deploy a liquid biopsy test that only requires a blood draw for cancer treatment selection, eliminating the need for most patients to travel to a hospital for biopsies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.